May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Nationwide Susceptibility Patterns of Common Ocular Pathogens: Results From Ocular TRUST
Author Affiliations & Notes
  • P. A. Asbell
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • D. F. Sahm
    Eurofins Anti-Infective Services, Herndon, Virginia
  • Ocular TRUST
    Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • Footnotes
    Commercial Relationships P.A. Asbell, Allergen Inc., Novartis International, AG, Pfizer, Inc., C; Alcon, Allergen, Novartis International AG, Bausch & Lomb, Vistakon Pharmaceuticals, R; D.F. Sahm, Vistakon Pharmaceuticals, LLC, F.
  • Footnotes
    Support Vistakon Pharmaceuticals, LLC
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4750. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. A. Asbell, D. F. Sahm, Ocular TRUST; Nationwide Susceptibility Patterns of Common Ocular Pathogens: Results From Ocular TRUST. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4750.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: Longitudinal surveillance of antimicrobial susceptibilities can detect emerging resistance trends and facilitate therapy selection. TRUST is an annual, ongoing, nationwide surveillance program recently expanded to ocular isolates. Ocular TRUST is the only nationwide surveillance program that prospectively collects and tests antimicrobial susceptibility in microbes cultured from eye infections. First-year results are presented for Streptococcus pneumoniae (SP) and Haemophilus influenzae (HI) ocular isolates.

Methods:: Samples were prospectively collected from geographically distributed U.S. institutions (28 community and 7 eye hospitals) between October 2005 and June 2006. All isolates were tested by broth microdilution according to CLSI methodology at a centralized independent laboratory. Microtiter panels included common ophthalmic antibiotics. MICs were interpreted as susceptible, intermediate, or resistant according to 2006 CLSI criteria.

Results:: All SP (n=49) and HI (n=32) isolates were 100% susceptible to the newer fluoroquinolones (FQs) levofloxacin, gatifloxacin, and moxifloxacin; ciprofloxacin SP susceptibility was 89.8%. Only one SP isolate was susceptible to tobramycin; all SP isolates were resistant to polymyxin B. Rank order of SP susceptibility to all antimicrobials tested: FQs > penicillin > trimethoprim > tobramycin > polymyxin B. All HI isolates were 100% susceptible to all antimicrobials tested except trimethoprim (81.3%). Prospective results for newer FQs (levofloxacin, gatifloxacin, moxifloxacin) correlated well with retrospective (1999-2006) susceptibility data in ocular isolates: ≥99.9% of SP (n=760) and 99.7% of HI (n=356).

Conclusions:: Susceptibility patterns in SP and HI ocular infections are identical for levofloxacin, gatifloxacin, and moxifloxacin, despite higher selection pressure for levofloxacin from a decade of widespread systemic use. Conversely, pathogen resistance limits the usefulness of polymyxin B and tobramycin in SP ocular infections (eg, bacterial conjunctivitis).

Keywords: bacterial disease • ocular irritancy/toxicity testing • antibiotics/antifungals/antiparasitics 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.